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Objective: To identify immunological evidence of Zika virus transmission in Thailand.
Methods: To undertake a preliminary serosurvey of possible exposure to Zika virus, 21
serum samples from cohort of acute undifferentiated fever patients were examined for
immunoreactivity to Zika, Dengue, Japanese encephalitis and Chikungunya envelope
antigens by Western blot analysis.
Results: Twenty of the 21 serum samples showed immunoreactivity to at least one of the
antigens, with seven samples showing immunoreactivity to all antigens. Of particular
note, two serum samples showed immunoreactivity only to Zika envelope antigen, with
no immunoreactivity to other envelope antigens.
Conclusions: This study presents the ﬁrst evidence of Zika virus transmission in
Thailand, although as yet the relationship between transmission and possible cases of
Zika fever in Thailand requires further investigation.1. Introduction
The family Flavivirus within the genus Flaviviridae contains
some of the most important mosquito transmitted viruses that
affect humans and animals. Particularly important mosquito
transmitted viruses in this family include Dengue virus (DENV),
Yellow fever virus, Japanese encephalitis virus (JEV) and West
Nile virus, which combined cause millions of infections every
year around the world. However, many of the other viruses in
this family also cause disease in humans or animals, but are
generally believed to have a more limited geographical range
and to cause few infections annually [1].
The mosquito transmitted Zika virus (family Flavivirus,
genus Flaviviridae) was ﬁrst isolated from a sentinel monkey in
the Zika forest near Entebbe, Uganda [2], and the ﬁrst reported
cases of human infection occurred in Nigeria in 1954 [3].
Since then, signiﬁcant outbreaks of Zika disease have occurredin Yap Island in the Federated States of Micronesia, and more
recently in French Polynesia and New Caledonia with this last
outbreak causing more than 8000 suspected cases [4]. Isolated
cases have been reported from the Philippines [5], Cambodia
[6] and Indonesia [7,8] and autochthonous transmission of Zika
has been reported in Brazil [9]. The virus has additionally been
detected in mosquitoes in Malaysia [10], and in travelers
returning from Malaysia [11] and Thailand [12,13]. However,
there have been no direct reports of Zika fever in the Thai
population.
The main vector of Zika virus in Africa is the Aedes afri-
canus mosquito [14], but Aedes aegypti mosquitoes, the main
vector of dengue in much of Southeast Asia and elsewhere,
are also capable of transmitting Zika virus [15] and it is
probable that other Aedes species such as Aedes albopictus,
Aedes polynesiensis and Aedes hensilli are also capable of
transmitting Zika virus to humans [16].
Zika fever has signiﬁcant similarities with dengue fever,
although there is no abrupt clinical onset. The main symptoms
are fever, rash, headache, muscle and joint pain, odema of the
hands and feet and non-purulent conjunctivitis [17–19]. While the
course of the disease is believed to be relatively self-limiting,
lasting some 4 d–7 d, the recent outbreak in French Polynesia
was marked by a number of cases of Guillain-Barre syndrome as
well as other complications after the initial Zika virus infection
[20].BY-NC-ND license (http://
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(sudden onset of fever, headache, rash), it is possible that cases
of Zika disease remain unreported in Thailand as a consequence
of a mis-identiﬁcation of the disease as dengue fever, com-
pounded by the lack of speciﬁc investigation for Zika fever. The
well known cross reaction of antibodies between ﬂaviviruses
could cause Zika infections to be serologically diagnosed as
dengue fever [21].
We have therefore undertaken a preliminary retrospective
serosurvey of 21 serum samples from a previously described
cohort of acute undifferentiated fever patients collected in
Thailand [22] to determine if there is any evidence of exposure to
Zika virus.
2. Materials and methods
2.1. Serum samples
The serum samples used in this study were collected as part
of a previously described prospective hospital based study on
adult patients with acute undifferentiated fever undertaken at a
hospital in Nakhon Ratchasima province in Northeastern
Thailand [22]. The study was approved by appropriate Ethical
Review subcommittees and written inform consent was
obtained from all study participants as previously documented
[22].
2.2. Synthetic gene construction
The entire capsid (C), premembrane/membrane (prM), and
envelope (E) gene sequence for Zika virus was commercially
synthesized (GeneScript, USA Inc.) based on the sequence of a
Cambodian isolate of Zika virus (isolate FSS13025), Genbank
number AFD30972.1. The Zika synthetic gene was codon-
optimized for efﬁcient expression in mammalian cells. The
Zika synthetic clone contained 2385 bp of C, prM, E of Zika
virus in the pUC57 plasmid vector.
A DNA fragment containing 19 amino acids of the capsid
region immediately upstream of prM, as well as the prM and E
sequences was ampliﬁed from the codon optimized construct
using Phusion High-Fidelity DNA polymerase (Thermo Fisher
Scientiﬁc, Waltham, MA) with NheⅠ-19CprME-Zika-Fw for-
ward primer (50-GAGCTAGCCACCATGGGAAGAGGGAC
CGATACAAGC-30) and 19CprME-Zika-EcoRⅠ-Rw reverse
primer (50-CGGAATTCTTATGCGGACACTGCGGTGGA-
CAGAAAA-30). After double digestion with NheⅠ and EcoRⅠ
restriction enzymes the product was ligated into NheⅠ and EcoRⅠ
double digested pCDNA™3.1(+) vector. The ligated products
were transformed into competent DH5-a Escherichia coli. After
conﬁrmation of the sequence by DNA sequence analysis, 3 mg of
the pCDNA3.1+_19CprME-Zika plasmid was transfected into
1.3 × 106 cells of HEK293T/17 cells in 6-well plate by the CaCl2
method. Cells were cultured in Opti-MEM and the culture su-
pernatant was collected at 2 d post-transfection.
2.3. Viral infection
HEK293T/17 cells were infected with either Chikungunya
virus (CHIKV) E1: 226V (ECSA: Thai isolate), DENV-2
(16681) or JEV (BJ-1) at MOI of 1 according to our standardprotocols [23–25] and cultured in Opti-MEM for two days after
which the culture supernatant was collected.
2.4. Western blot analysis
Opti-MEM, culture supernatant from the
pCDNA3.1+_19CprME-Zika transfection and culture superna-
tants from CHIKV, DENV-2 and JEV infections were resus-
pended in a non-reducing loading dye and electrophoresed
through 10% SDS-PAGE gels with a protein marker (161-0373,
precision plus protein™ all blue prestained standards). Proteins
were transferred onto nitrocellulose membranes (Hybon-
d™ECL™ code: RPN303D, GE Healthcare, Little Chalfont,
UK). The membranes were blocked with 5% skim milk for 1 h
and incubated with following antibodies; a 1:1000 dilution of
HB112 (a mouse monoclonal anti-ﬂavivirus group antigen
antibody [26]), a 1:1000 dilution of a mouse monoclonal anti-
Alphavirus antibody (sc-58088, Santa Cruz Biotechnology,
Santa Cruz, USA) or a 1:1000 dilution of human serum for 1 h.
After washing, membranes were incubated for 1 h with an
appropriate secondary antibody, namely either a HRP-
conjugated rabbit anti-mouse IgG (A9044, Sigma St. Louis,
USA) or a HRP-conjugated goat anti-human IgG (62-8420,
Thermo Fisher Scientiﬁc). The membranes were washed and
incubated with chemiluminescent substrate (RPN2232, GE
Healthcare) prior detecting the signal by the chemiluminescent
Western blot imaging system Azure c400.
3. Results
A synthetic gene construct containing the codon optimized
sequence of a recently reported Cambodian Zika virus isolate
(Genbank number AFD30972.1) encompassing the last 19 co-
dons of the C sequence and the prM and E genes was transfected
into Hek293T/17 cells and the supernatant collected on day two
post transfection. In parallel HeK293T/17 cells were infected
with CHIKV, JEV or DENV-2 and supernatants were collected
on day two post infection. Aliquots of these supernatants were
electrophoresed though standard SDS-PAGE gels, and the pro-
teins were transferred to nitrocellulose membranes. A total of 26
ﬁlters were prepared. Five of the ﬁlters were used in control
Western blots with a mouse monoclonal pan ﬂavivirus antibody
(HB112), with an anti-alphavirus antibody, a combination of
both antibodies and with two secondary antibodies (a rabbit anti-
mouse IgG and a goat anti-human IgG). Results (Figure 1) show
the pan-ﬂavivirus antibody was able to detect Zika, DENV and
JEV envelope antigens with no cross reactivity to CHIKV en-
velope antigen, while conversely the anti-alphavirus antibody
was able to detect CHIKV envelope antigen with no cross
reactivity to the ﬂaviviruses (Zika, DENV and JEV). The two
secondary antibodies showed no immunoreactivity to any of the
envelope antigens. Equivalent ﬁlters were then used in western
blot analyses with 21 serum samples individually. Results
showed a complex pattern of immunoreactivity (Table 1 and
Figure 1). Only 1 sample showed no immunoreactivity with any
of the antigens. Immunoreactivity to the CHIKV envelope an-
tigen was seen in 13/21 (61%) of samples, while the corre-
sponding ﬁgures for JEV, Zika and DENV envelope antigens
were 14/21 (66%), 16/21 (76%) and 17/21 (80%) respectively. A
total of 7 samples showed immunoreactivity to all antigens.
Figure 1. Representative western blots.
Nitrocellulose ﬁlters with CHIKV (C) Zika (Z) DENV (D) and JEV (J) envelope antigens were incubated with a pan-ﬂavivirus monoclonal antibody (HB112),
an anti-alphavirus monoclonal antibody (alphavirus) or a combination of both (HB112 + Alphavirus) or the respective secondary antibodies alone (Rabbit
anti-mouse IgG-HRP and goat anti-human IgG-HRP) or with human serum (S2, S12 and S6). Serum sample S6 shows immunoreactivity to Zika only.
Table 1
Summary of immunoreactivity to 4 arboviral antigens.
Serum O CHIKV Zika DENV JEV
S1 − − + + +
S2 − + + + +
S3 − + + + −
S4 − + − + −
S5 − + + + +
S6 − − + − −
S7 − + + + −
S8 − + + + +
S9 − + + − +
S10 − − − − −
S11 − + + + −
S12 − − + + +
S13 − − + + +
S14 − + + + +
S15 − + + + +
S16 − − + − −
S17 − − − + +
S18 − − − + +
S19 − + + + +
S20 − + − + +
S21 − + + + +
Total 0 13 16 17 14
+ Immunoreactivity; − No immunoreactivity detected.
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Zika envelope antigen.
4. Discussion
Dengue is endemic in Thailand, and studies have shown that
DENV neutralizing antibodies can be found in more than 95% of
the Thai population [27]. Similarly, Thailand introduced a JEV
vaccination campaign in 1990, some 25 y ago [28] although JEV
remains an important cause of encephalitis in Thailand [29]. As
such, the high level of immunoreactivity to DENV and JEV
envelope antigens is unsurprising. However, as a consequence
of either DENV infection or JEV vaccination/infection bothneutralizing and broadly cross reactive antibodies are generated
[30]. An original concern of this study was that anti Zika
envelope immunoreactivity seen in the samples would occur as
a consequence of cross reactive anti-DENV or anti-JEV anti-
bodies, as has been observed by others [21]. However, in two cases
immunoreactivity to only the Zika envelope antigen was
observed, strongly suggesting that this is bone ﬁde
immunoreactivity to Zika envelope antigen, and not a
consequence of cross-reactivity of antibodies from either
DENV infection or JEV vaccination/infection.
The levels of immunoreactivity to the CHIKV envelope an-
tigen were somewhat surprising. While there was a large
outbreak of CHIKV in Thailand in 2009/2010, this was largely
conﬁned to the southern part of Thailand, while the samples in
this cohort came from a study undertaken in the Northeastern
part of Thailand. However, it has been shown that CHIKV
neutralizing antibodies are extremely long lasting [31], and
Thailand has had outbreaks of CHIKV before the 2009/2010
outbreak as a consequence of circulation of the indigenous
Asian lineage [32].
While the study was undertaken on samples obtained on day
of hospital admission for acute undifferentiated fever [22], it
remains unclear as to whether any of the cases were indeed
Zika fever. Given that our study investigated the presence of
IgG antibodies and that the serum samples were obtained on
the day of admission, it is unlikely that admission was as a
consequence of Zika fever, although to determine this, far
more sensitive and appropriate tools will be required.
However, the results from this study suggest that the
development of more speciﬁc tools, such as neutralization
assays to measure neutralizing antibodies is urgently required,
especially as our study supports the active transmission of
Zika virus in Thailand.
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